Wujcik Debra
Vanderbilt-Ingram Cancer Center, Clinical Trials Office, 9th Floor, 1818 Albion Street, Nashville, TN 37208, USA.
Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):5-9. doi: 10.1016/j.soncn.2006.01.010.
To review the biology of the EGFR, its structure, and the associated signal transduction pathways. To provide an overview of the role of EGFR in normal physiology and the pathophysiology of malignancy. Current anti-EGFR treatments are also discussed.
Research articles.
EGFR is a valid target in the treatment of solid tumors. EGFR abnormalities and dysfunction are involved in various aspects of carcinogenesis and tumor progression, and EGFR is overexpressed in several tumor types. The development of anti-EGFR therapies represents an important advance in cancer therapy.
Anti-EGFR therapy is currently available in the clinical setting. Nurses involved in the care of patients with cancer can benefit from an increased understanding of the normal and abnormal function of EGFR in the body and the mechanisms by which anti-EGFR therapies act.
回顾表皮生长因子受体（EGFR）的生物学特性、其结构以及相关的信号转导途径。概述EGFR在正常生理学和恶性肿瘤病理生理学中的作用。同时讨论当前的抗EGFR治疗方法。
研究文章。
EGFR是实体瘤治疗中的一个有效靶点。EGFR异常和功能障碍涉及癌症发生和肿瘤进展的各个方面，并且EGFR在几种肿瘤类型中过度表达。抗EGFR疗法的发展是癌症治疗的一项重要进展。
抗EGFR疗法目前已应用于临床。参与癌症患者护理的护士可以通过增加对EGFR在体内的正常和异常功能以及抗EGFR疗法作用机制的了解而受益。
